NFS1 and colorectal cancer: Furthermore, a recent study revealed that inhibiting the enzyme NFS1 or its phosphorylation can enhance the sensitivity of colorectal cancer cells to oxaliplatin by promoting PANoptosis, leading to improved chemotherapy outcomes (22).